BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 23873170)

  • 1. CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
    Pelosof L; Yerram SR; Ahuja N; Delmas A; Danilova L; Herman JG; Azad NS
    Int J Cancer; 2014 Feb; 134(3):596-605. PubMed ID: 23873170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype.
    Baretti M; Karunasena E; Zahurak M; Walker R; Zhao Y; Pisanic TR; Wang TH; Greten TF; Duffy AG; Gootjes E; Meijer G; Verheul HMW; Ahuja N; Herman JG; Azad NS
    Clin Transl Sci; 2021 May; 14(3):954-963. PubMed ID: 33811727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.
    Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
    Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer.
    Hagiwara T; Sugimoto K; Momose H; Irie T; Honjo K; Okazawa YU; Kawai M; Kawano S; Munakata S; Takahashi M; Kojima Y; Serizawa N; Nagahara A; Hoffman RM; Brock MV; Sakamoto K
    Anticancer Res; 2022 Feb; 42(2):697-707. PubMed ID: 35093868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
    Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
    Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
    Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
    Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
    Morioka Y; Hibi K; Sakai M; Koike M; Fujiwara M; Kodera Y; Ito K; Nakao A
    Anticancer Res; 2006; 26(6B):4267-70. PubMed ID: 17201143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer.
    Arnold CN; Goel A; Compton C; Marcus V; Niedzwiecki D; Dowell JM; Wasserman L; Inoue T; Mayer RJ; Bertagnolli MM; Boland CR
    Cancer Biol Ther; 2004 Jan; 3(1):73-8. PubMed ID: 14726676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans.
    Ashktorab H; Smoot DT; Farzanmehr H; Fidelia-Lambert M; Momen B; Hylind L; Iacosozio-Dononue C; Carethers JM; Goel A; Boland CR; Giardiello FM
    Int J Cancer; 2005 Oct; 116(6):914-9. PubMed ID: 15856472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
    Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
    Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
    Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
    Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
    Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S
    Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.
    Oki E; Zhao Y; Yoshida R; Masuda T; Ando K; Sugiyama M; Tokunaga E; Morita M; Kakeji Y; Maehara Y
    World J Gastroenterol; 2009 May; 15(20):2520-5. PubMed ID: 19469003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
    Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
    Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
    Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
    Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
    Ogi K; Toyota M; Mita H; Satoh A; Kashima L; Sasaki Y; Suzuki H; Akino K; Nishikawa N; Noguchi M; Shinomura Y; Imai K; Hiratsuka H; Tokino T
    Cancer Biol Ther; 2005 Jul; 4(7):773-80. PubMed ID: 16123600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
    Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
    Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
    Leichman L; Groshen S; O'Neil BH; Messersmith W; Berlin J; Chan E; Leichman CG; Cohen SJ; Cohen D; Lenz HJ; Gold P; Boman B; Fielding A; Locker G; Cason RC; Hamilton SR; Hochster HS
    Oncologist; 2016 Feb; 21(2):172-7. PubMed ID: 26786262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.